Market Place
Sourcing Support
Biosight Launches a Phase 1/2 Trial of Aspacytarabine with Venetoclax
22 Nov 2022 //
PRNEWSWIRE
BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
22 Sep 2022 //
GLOBENEWSWIRE
Biosight Granted ODD from FDA for Aspacytarabine for Myelodysplastic Syndromes
01 Aug 2022 //
PRNEWSWIRE
Biosight Shows Final Primary Endpoint Data from Phase 2b Study of BST-236 in AML
06 Jan 2022 //
GLOBENEWSWIRE
Biosight Initiates Phase 2 Clinical Trial of Aspacytarabine for MDS and AML
12 Nov 2021 //
GLOBENEWSWIRE
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
11 Nov 2021 //
GLOBENEWSWIRE
ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight
03 Nov 2021 //
GLOBENEWSWIRE
Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results
10 Sep 2021 //
GLOBENEWSWIRE
Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine
16 Aug 2021 //
GLOBENEWSWIRE
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
06 Jul 2021 //
GLOBENEWSWIRE
BioSight completes enrollment in phase 2b study of aspacytarabine
12 May 2021 //
PHARMABIZ
Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study
28 Apr 2021 //
GLOBENEWSWIRE
Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study
07 Dec 2020 //
GLOBENEWSWIRE
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
02 Dec 2020 //
GLOBENEWSWIRE
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral
25 Mar 2020 //
BUSINESSINSIDER
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.